306 related articles for article (PubMed ID: 32188714)
1. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer.
Kim SY; Kim TW
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32188714
[TBL] [Abstract][Full Text] [Related]
2. Promising New Agents for Colorectal Cancer.
Das S; Ciombor KK; Haraldsdottir S; Goldberg RM
Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549
[TBL] [Abstract][Full Text] [Related]
3. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL; Lenz HJ
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
[TBL] [Abstract][Full Text] [Related]
5. Current and future biomarkers in the treatment of colorectal cancer.
Cuyle PJ; Prenen H
Acta Clin Belg; 2017 Apr; 72(2):103-115. PubMed ID: 27917697
[TBL] [Abstract][Full Text] [Related]
6. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.
Giordano G; Parcesepe P; Bruno G; Piscazzi A; Lizzi V; Remo A; Pancione M; D'Andrea MR; De Santis E; Coppola L; Pietrafesa M; Fersini A; Ambrosi A; Landriscina M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299337
[TBL] [Abstract][Full Text] [Related]
7. Metastatic colorectal cancer- third line therapy and beyond.
Foo T; Roy A; Karapetis C; Townsend A; Price T
Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
[TBL] [Abstract][Full Text] [Related]
8. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
[TBL] [Abstract][Full Text] [Related]
10. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
11. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
Corti G; Bartolini A; Crisafulli G; Novara L; Rospo G; Montone M; Negrino C; Mussolin B; Buscarino M; Isella C; Barault L; Siravegna G; Siena S; Marsoni S; Di Nicolantonio F; Medico E; Bardelli A
Clin Colorectal Cancer; 2019 Jun; 18(2):91-101.e3. PubMed ID: 30981604
[TBL] [Abstract][Full Text] [Related]
12. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
13. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
14. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
Włodarczyk M; Włodarczyk J; Siwiński P; Sobolewska-Włodarczyk A; Fichna J
Curr Drug Targets; 2018; 19(15):1731-1737. PubMed ID: 30073926
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
16. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
Baek SK; Lee KT; Bae SB; Lee SC
Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
[TBL] [Abstract][Full Text] [Related]
19. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
20. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
Davis LE
Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]